Continuing the use of disease-modifying therapies (DMTs) in patients with secondary-progressive MS (SPMS) who are actively relapsing is justified, new research findings suggest.
At ECTRIMS 2018, Dr Nathaniel Lizak from the Clinical Outcomes Research (CORe) Unit at the University of Melbourne, Australia, presented the details of a study set up to evaluate factors influencing the rate of disability accumulation and progression in patients with SPMS.
Want to read more?
Log in or sign up to access all Neurodiem content.
Already have an account? Log In
Ology Medical Education is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.
No responsibility is assumed by Ology Medical Education for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, Ology Medical Education recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of Ology Medical Education or the sponsor. Ology Medical Education assumes no liability for any material contained herein.